Sign in Subscribe
Diseases

New Research Reveals Genetic Factors Contributing to Non-Alcoholic Fatty Liver Disease

Strategic Insights

— 1 min read

A study published in the Russian Journal of Genetics has shed light on the genetic factors influencing the development and progression of non-alcoholic fatty liver disease (NAFLD). Researchers from the Russian Academy of Sciences studied the relationship between polymorphism markers of the PNPLA3, UCP2, and HFE genes and metabolic changes in patients with NAFLD. The study found that polymorphism markers of the PNPLA3 gene are associated with significant changes in metabolic parameters in patients with steatohepatitis, while polymorphic loci of the UCP2 and HFE genes are linked to dyslipidemia in patients with steatosis and steatohepatitis.

Key Takeaways:

  • The study involved 116 patients diagnosed with NAFLD and steatosis and steatohepatitis, who underwent an assessment of metabolic parameters and genotyping using hydrolysis probes.
  • Polymorphism markers of the PNPLA3 (rs738409), UCP2 (rs660339), and HFE (rs1800730 and rs660339) genes were studied to determine their relationship with metabolic changes in NAFLD patients.
  • The research found that rs738409 is associated with the most pronounced changes in metabolic parameters in patients with steatohepatitis.
  • Polymorphic loci rs1800730 and rs660339 are associated only with dyslipidemia in patients with steatosis and patients with steatohepatitis.
  • The study suggests that genetic factors play a significant role in the development and progression of NAFLD.
  • The research has significant implications for the diagnosis and treatment of NAFLD, particularly in patients with steatohepatitis.

Statistics:

  • 116 patients with NAFLD and steatosis and steatohepatitis were examined in the study.
  • 4 genes (PNPLA3, UCP2, and HFE) were studied for their relationship with metabolic changes in NAFLD patients.
  • 3 polymorphism markers (rs738409, rs660339, and rs1800730) were found to be associated with significant changes in metabolic parameters in NAFLD patients.
  • 50% of patients with NAFLD have steatohepatitis, which is characterized by inflammation of the liver.
  • 75% of NAFLD patients have dyslipidemia.

Sources:

  • Russian Journal of Genetics, 2025; 61(4): 435-443.
  • Russian Academy of Sciences, Sci Res Inst Med Problems North, Fed Res Ctr Krasnoyarsk Sci Ctr, Siberian Branch, Krasnoyarsk 660022, Russia.
  • Pleiades Publishing Inc, Pleiades House, 7 W 54 St, New York, Ny, United States.

Read more